ViroMed Approved to Start Trial of Gene Therapy for Ischemic Heart Disease

ViroMed of South Korea has obtained Investigational New Drug approval for VM202, its lead gene therapy drug candidate, from Korea's Ministry of Food and Drug Safety (MFDS). ViroMed will conduct a Phase II trial of the drug in 108 Korean patients with ischemic heart disease (IHD); the goal is to increase heart function by forming new blood vessels. VM202 has already started two Phase III trials: one in patients with diabetic peripheral neuropathy (DPN) and the other for ischemic diabetic foot ulcer. More details.... Stock Symbol: (KOSDAQ: 084990) Share this with colleagues: // //